Position Paper on Practicable Performance Criteria for the Removal Efficiency of Volatile Radionuclides

As a result of fuel reprocessing, volatile radionuclides may be released from the facility stack if no processes are put in place to remove them. The radionuclides that are of concern in this document are 3H, 14C, 85Kr, and 129I. The question we attempted to answer is how efficient must this removal process be for each of these radionuclides? To answer this question, we examined the three regulations that may impact the degree to which these radionuclides must be reduced before process gases can be released from the facility. These regulations are 40 CFR 61 (EPA 2010a), 40 CFR 190(EPA 2010b), and 10 CFR 20 (NRC 2012). These regulations apply to the total radionuclide release and to a particular organ - the thyroid. Because these doses can be divided amongst all the radionuclides in different ways and even within the four radionuclides in question, we provided several cases. We first looked at the inventories for these radionuclides for three fuel types (PWR UOX, PWR MOX, and AHTGR), several burn-up values, and time out of reactor extending to 200 y. We calculated doses to the maximum exposed individual (MEI) with the EPA code CAP-88 (Rosnick 1992). Finally, we looked at two dose cases. Allocating all of the allowable dose to be used by the volatile radionuclides is one case, but, perhaps, unrealistic. In lieu of this, we arbitrarily selected a value of 10% of the allowable dose to be assigned to the volatile radionuclides. We calculated the required decontamination factors (DFs) for both of these cases, including the case for the thyroid dose for which 14C and 129I were the main contributors. With respect to 129I doses, we found that the highest dose was calculated with iodine as a fine particulate. The dose scaled as the fraction of the total 129I that was particulate. Therefore, we assumed for all of our calculations that 100% of the 129I was particulate and allow the user of the results given here to scale our calculated doses to their needs

Technology Insights and Perspectives for Nuclear Fuel Cycle Concepts

The following report provides a rich resource of information for exploring fuel cycle characteristics. The most noteworthy trends can be traced back to the utilization efficiency of natural uranium resources. By definition, complete uranium utilization occurs only when all of the natural uranium resource can be introduced into the nuclear reactor long enough for all of it to undergo fission. Achieving near complete uranium utilization requires technologies that can achieve full recycle or at least nearly full recycle of the initial natural uranium consumed from the Earth. Greater than 99% of all natural uranium is fertile, and thus is not conducive to fission. This fact requires the fuel cycle to convert large quantities of non-fissile material into fissile transuranics. Step increases in waste benefits are closely related to the step increase in uranium utilization going from non-breeding fuel cycles to breeding fuel cycles. The amount of mass requiring a disposal path is tightly coupled to the quantity of actinides in the waste stream. Complete uranium utilization by definition means that zero (practically, near zero) actinide mass is present in the waste stream. Therefore, fuel cycles with complete (uranium and transuranic) recycle discharge predominately fission products with some actinide process losses. Fuel cycles without complete recycle discharge a much more massive waste stream because only a fraction of the initial actinide mass is burned prior to disposal. In a nuclear growth scenario, the relevant acceptable frequency for core damage events in nuclear reactors is inversely proportional to the number of reactors deployed in a fuel cycle. For ten times the reactors in a fleet, it should be expected that the fleet-average core damage frequency be decreased by a factor of ten. The relevant proliferation resistance of a fuel cycle system is enhanced with: decreasing reliance on domestic fuel cycle services, decreasing adaptability for technology misuse, enablement of material accountability, and decreasing material attractiveness

Technology Insights and Perspectives for Nuclear Fuel Cycle Concepts

The following report provides a rich resource of information for exploring fuel cycle characteristics. The most noteworthy trends can be traced back to the utilization efficiency of natural uranium resources. By definition, complete uranium utilization occurs only when all of the natural uranium resource can be introduced into the nuclear reactor long enough for all of it to undergo fission. Achieving near complete uranium utilization requires technologies that can achieve full recycle or at least nearly full recycle of the initial natural uranium consumed from the Earth. Greater than 99% of all natural uranium is fertile, and thus is not conducive to fission. This fact requires the fuel cycle to convert large quantities of non-fissile material into fissile transuranics. Step increases in waste benefits are closely related to the step increase in uranium utilization going from non-breeding fuel cycles to breeding fuel cycles. The amount of mass requiring a disposal path is tightly coupled to the quantity of actinides in the waste stream. Complete uranium utilization by definition means that zero (practically, near zero) actinide mass is present in the waste stream. Therefore, fuel cycles with complete (uranium and transuranic) recycle discharge predominately fission products with some actinide process losses. Fuel cycles without complete recycle discharge a much more massive waste stream because only a fraction of the initial actinide mass is burned prior to disposal. In a nuclear growth scenario, the relevant acceptable frequency for core damage events in nuclear reactors is inversely proportional to the number of reactors deployed in a fuel cycle. For ten times the reactors in a fleet, it should be expected that the fleet-average core damage frequency be decreased by a factor of ten. The relevant proliferation resistance of a fuel cycle system is enhanced with: decreasing reliance on domestic fuel cycle services, decreasing adaptability for technology misuse, enablement of material accountability, and decreasing material attractiveness

Eliminating Medical Waste Liabilities Through Mobile Maceration and Disinfection

Commercial medical waste treatment technologies include incineration, melting, autoclaving, and chemical disinfection. Incineration disinfects, destroys the original nature of medical waste, and reduces the waste volume by converting organic waste content to carbon dioxide and water, leaving only residual inorganic ash. However, medical waste incinerator numbers have plummeted from almost 2,400 in 1995 to 115 in 2003 and to about 62 in 2005, due to negative public perception and escalating compliance costs associated with increasingly strict regulations. High-temperature electric melters have been designed and marketed as incinerator alternatives, but they are also costly and generally must comply with the same incinerator emissions regulations and permitting requirements. Autoclave processes disinfect medical waste at much lower operating temperatures than incinerators operate at, but are sometimes subject to limitations such as waste segregration requirements to be effective. Med-Shred, Inc. has developed a patented mobile shredding and chemical disinfecting process for on-site medical waste treatment. Medical waste is treated on-site at customer facilities by shredding and disinfecting the waste. The treated waste can then be transported in compliance with Health Insurance Portability and Accountability Act of 1996 (HIPAA) requirements to a landfill for disposal as solid municipal waste. A team of Idaho National Laboratory engineers evaluated the treatment process design. The process effectiveness has been demonstrated in mycobacterium tests performed by Analytical Services Incorporated. A process description and the technical and performance evaluation results are presented in the paper. A treatment demonstration and microbiological disinfecting tests show that the processor functions as it was intended

Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study

Background: Long-term outcome in multiple sclerosis (MS) depends on early treatment. In patients with acute optic neuritis (ON), an early inflammatory event, we investigated markers in cerebrospinal fluid (CSF), which may predict a diagnosis of MS. Methods: Forty patients with acute ON were recruited in a prospective population-based cohort with median 29 months (range 19–41) of follow-up. Paired CSF and serum samples were taken within 14 days (range 2–38), prior to treatment. Prospectively, 16/40 patients were by a uniform algorithm diagnosed with MS (MS-ON) and 24 patients continued to manifest isolated ON (ION) during follow-up. Levels of cytokines and neurofilament light chain (NF-L) were measured at the onset of acute ON and compared to healthy controls (HC). Significance levels were corrected for multiple comparisons (“q”). The predictive value of biomarkers was determined with multivariable prediction models using nomograms. Results: CSF TNF-α, IL-10, and CXCL13 levels were increased in MS-ON compared to those in ION patients (q = 0.021, 0.004, and 0.0006, respectively). MS-ON patients had increased CSF pleocytosis, IgG indices, and oligoclonal bands (OCBs) compared to ION (q = 0.0007, q = 0.0058, and q = 0.0021, respectively). CSF levels of IL-10, TNF-a, IL-17A, and CXCL13 in MS-ON patients correlated with leukocyte counts (r > 0.69 and p < 0.002) and IgG index (r > 0.55, p < 0.037). CSF NF-L levels were increased in ON patients compared to those in HC (q = 0.0077). In MS-ON, a progressive increase in NF-L levels was observed at 7 to 14 days after disease onset (r = 0.73, p < 0.0065). Receiver-operating characteristic (ROC) curves for two multivariable prediction models were generated, with IL-10, CXCL13, and NF-L in one (“candidate”) and IgG index, OCB, and leukocytes in another (“routine”). Area under the curve was 0.89 [95% CI 0.77–1] and 0.86 [0.74–0.98], respectively. Predictions of the risk of MS diagnosis were illustrated by two nomograms. Conclusions: CSF TNF-α, IL-10, CXCL13, and NF-L levels were associated with the development of MS, suggesting that the inflammatory and neurodegenerative processes occurred early. Based on subsequent diagnosis, we observed a high predictive value of routine and candidate biomarkers in CSF for the development of MS in acute ON. The nomogram predictions may be useful in the diagnostic work-up of MS

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals, and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk. Modestly powered genome-wide association studies (GWAS) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility. Most of the genetic architecture underlying susceptibility to the disease remains to be defined and is anticipated to require the analysis of sample sizes that are beyond the numbers currently available to individual research groups. In a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, we have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci. Within the MHC we have refined the identity of the HLA-DRB1 risk alleles and confirmed that variation in the HLA-A gene underlies the independent protective effect attributable to the class I region. Immunologically relevant genes are significantly overrepresented among those mapping close to the identified loci and particularly implicate T-helper-cell differentiation in the pathogenesis of multiple sclerosis

Hypericum sp.: essential oil composition and biological activities

Phytochemical composition of Hypericum genus has been investigated for many years. In the recent past, studies on the essential oils (EO) of this genus have been progressing and many of them have reported interesting biological activities. Variations in the EO composition of Hypericum species influenced by seasonal variation, geographic distribution, phenological cycle and type of the organ in which EO are produced and/or accumulated have also been reported. Although many reviews attributed to the characterization as well as biological activities of H. perforatum crude extracts have been published, no review has been published on the EO composition and biological activities of Hypericum species until recently (Crockett in Nat Prod Commun 5(9):1493–1506, 2010; Bertoli et al. in Global Sci Books 5:29–47, 2011). In this article, we summarize and update information regarding the composition and biological activities of Hypericum species EO. Based on experimental work carried out in our laboratory we also mention possible biotechnology approaches envisaging EO improvement of some species of the genus.Fundação para a Ciência e a Tecnologia (FCT) - project PTDC/AGR AAM/70418/2006, SFRH/BD/ 13283/2003

Longitudinal retinal changes in MOGAD

OBJECTIVE: Patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro-axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON-independent retinal atrophy can be detected in MOGAD. METHODS: Eighty MOGAD patients and 139 healthy controls (HC) were included. OCT data was acquired with 1) Spectralis spectral domain OCT (MOGAD (N=66) and HC (N=103)) and 2) Cirrus HD-OCT (MOGAD (N=14) and HC (N=36)). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fibre layer (pRNFL) were quantified. RESULTS: At baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD-ON) compared with MOGAD eyes without a history of ON (MOGAD-NON) and HC (p12 months ago (p<0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with HC. INTERPRETATION: Our study suggests the absence of attack-independent retinal damage in MOGAD. Yet, ongoing neuroaxonal damage or oedema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in MOGAD. This article is protected by copyright. All rights reserved